Nanjing's Triastek Completes $50 Million Round for 3D Printing of Drugs

Triastek of Nanjing completed a $50 million Series B financing to advance its 3D printed pharmaceutical technology. The company has the first drug candidate from its portfolio in clinical trials and is developing the new manufacturing technology for general use. Triastek says Melt Extrusion Deposition (MED®) 3D printing is an additive manufacturing process that precisely deposits each layer of melted excipients, APIs and their mixture materials. It produces a drug delivery system with well-designed geometric structures. The round was co-led by Matrix Partners China and CPE. More details.... Share this with colleagues: // //